Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Gotham Therapeutics was a biotechnology company focused on the discovery and development of novel therapeutics by targeting RNA-modifying proteins, a field known as epitranscriptomics. Founded in 2017, the company aimed to translate cutting-edge science in RNA biology into transformative medicines for various diseases. In October 2021, Gotham Therapeutics merged with RNATICS GmbH to form transcripta bio, combining expertise in small molecule discovery targeting RNA-modifying enzymes with RNA biology and oligonucleotide development to create a new leader in RNA therapeutics.
The New York headquarters served as the primary center for research and development operations, strategic planning, and corporate administration for Gotham Therapeutics prior to its merger.
Likely located within a specialized life science facility such as the Alexandria Center for Life Science, providing access to advanced laboratory infrastructure and a collaborative biotech ecosystem.
As a venture-backed biotech startup, the work culture was likely dynamic, innovative, and science-driven, characterized by a fast-paced environment focused on achieving research milestones and fostering collaboration.
The headquarters was central to Gotham's pioneering efforts in epitranscriptomics, housing the core scientific team and technology driving its drug discovery programs.
Prior to its merger, Gotham Therapeutics was primarily focused on research and development activities within the United States. Its investor base included international venture capital firms, indicating a global outlook for its scientific and business development efforts. Collaborations and partnerships might have extended its reach internationally, typical for biotech companies in the discovery phase.
450 East 29th Street
New York
NY
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Gotham Therapeutics' leadership includes:
Gotham Therapeutics has been backed by several prominent investors over the years, including:
In its final year of independent operation (approx. October 2020 - October 2021), the most significant corporate event for Gotham Therapeutics was its merger with RNATICS to form transcripta bio. This led to an integration of leadership teams into the new entity. Specific high-profile individual executive hires or departures at Gotham Therapeutics, separate from the merger, were not widely publicized during this period.
Discover the tools Gotham Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its merger and the deactivation of its independent domain, Gotham Therapeutics likely used standard corporate email formats. Common formats in the biotech industry include [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com]. Emails to @gothamtx.com are no longer active.
[first_initial][last]@gothamtx.com or [first].[last]@gothamtx.com
Format
lbabiss@gothamtx.com (example, historical, not active)
Example
0%
Success rate
Company Press Release / Fierce Biotech • April 4, 2019
Gotham Therapeutics announced its official launch with $54 million in Series A financing. The round was co-led by Versant Ventures and Forbion, with participation from SR One and Celgene. The company was founded to discover and develop new medicines by targeting proteins involved in epitranscriptomics....more
Company Press Release / BioSpace • October 13, 2021
Gotham Therapeutics and RNATICS GmbH announced their merger to form transcripta bio. The newly formed company aims to leverage Gotham's expertise in epitranscriptomics and small molecule drug discovery with RNATICS' capabilities in RNA biology, bioinformatics, and oligonucleotide development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Gotham Therapeutics, are just a search away.